Stifel starts Lexeo at buy, cites ataxia and Alzheimer’s drug candidates (LXEO) Markets December 1, 2023 [ad_1] ismagilov Stifel has began protection of newly public Lexeo Therapeutics (NASDAQ:LXEO) with a purchase ranking, saying it was bullish…
